Prokineticin 2 promotes macrophages-me diated antibacterial host defense against bacterial pneumonia

作者全名："Tu, Qianqian; Yu, Xiaoyan; Xie, Wei; Luo, Yetao; Tang, Hong; Chen, Kai; Ruan, Yanting; Li, Yue; Zhou, Jie; Yin, Yibing; Chen, Dapeng; Song, Zhixin"

作者地址："[Tu, Qianqian; Yu, Xiaoyan; Xie, Wei; Ruan, Yanting; Zhou, Jie; Chen, Dapeng; Song, Zhixin] Chongqing Med Univ, Childrens Hosp, Dept Clin Lab, 136 Zhongshaner Rd, Chongqing 400014, Peoples R China; [Tu, Qianqian; Yu, Xiaoyan; Xie, Wei; Ruan, Yanting; Zhou, Jie; Chen, Dapeng; Song, Zhixin] Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China; [Tu, Qianqian; Yu, Xiaoyan; Xie, Wei; Ruan, Yanting; Zhou, Jie; Chen, Dapeng; Song, Zhixin] Chongqing Med Univ, Childrens Hosp, Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China; [Tu, Qianqian; Yu, Xiaoyan; Xie, Wei; Ruan, Yanting; Zhou, Jie; Chen, Dapeng; Song, Zhixin] Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Child Infect & Immun, Chongqing, Peoples R China; [Tu, Qianqian; Chen, Kai; Yin, Yibing] Chongqing Med Univ, Dept Lab Med, Key Lab Diagnost Med, Chongqing, Peoples R China; [Luo, Yetao] Army Med Univ, Affiliated Hosp 2, Dept Nosocomial Infect Control, Chongqing, Peoples R China; [Tang, Hong] Chongqing Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Dept Surg Intens Care Unit, Chongqing, Peoples R China; [Li, Yue] Chongqing Med Univ, Coll Basic Med Sci, Mol Med & Canc Res Ctr, Chongqing, Peoples R China"

通信作者："Chen, DP; Song, ZX (通讯作者)，Chongqing Med Univ, Childrens Hosp, Dept Clin Lab, 136 Zhongshaner Rd, Chongqing 400014, Peoples R China."

来源：INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000965649700008

JCR分区：Q1

影响因子：8.4

年份：2022

卷号：125

期号：　

开始页：103

结束页：113

文献类型：Article

关键词：Prokineticin 2; Pneumonia; Immune protection; Macrophages

摘要："Objectives: Bacterial pneumonia is a common serious infectious disease with high morbidity and mortality. Prokineticin 2 (PK2) has recently been identified as a novel immunomodulator in a variety of diseases; however, its role in bacterial pneumonia remains unclear. Methods: The levels of PK2 were measured and analyzed in patients with pneumonia and healthy controls. The effects of PK2 on the host response to pneumonia were evaluated by in vivo animal experiments and in vitro cell experiments. Results: PK2 levels dramatically decreased in patients with pneumonia compared with healthy controls, and PK2 levels were lower in patients with severe pneumonia than in pneumonia. In a mouse model of bacterial pneumonia, transtracheal administration of recombinant PK2 significantly alleviated lung injury and improved the survival, which was associated with increased host's bacterial clearance capacity, as manifested by decreased pulmonary bacterial loads. PK2 enhanced the chemotaxis, phagocytosis, and killing ability of macrophages, whereas the protective efficacy of PK2 was abolished after macrophage depletion. Conclusion: Impaired alveolar macrophage function caused by decreased PK2 is a new endogenous cause of the occurrence and development of bacterial pneumonia. The administration of recombinant PK2 may be a potential adjuvant therapy for bacterial pneumonia. (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)"

基金机构："National Natural Science Foundation of China [82272399, 81801956, 82102453]; Chongqing Municipal Health Commission [2020MSXM050]; Distinguished Young Scholars of the Children's Hospital of Chongqing Medical University; Chongqing Science and Technology Commission [cstc2019jcyj-msxmX0364]; CQMU (Chongqing Medical University) Program for Youth Innovation in Future Medicine"

基金资助正文："This study was supported by the National Natural Science Foundation of China (Grant Number: 82272399 to Dr. Chen, 81801956 to Dr. Song, and 82102453 to Dr. Zhou), Chongqing Municipal Health Commission (Grant Number: 2020MSXM050 to Prof. Chen), Distinguished Young Scholars of the Children's Hospital of Chongqing Medical University (to Dr. Song), Chongqing Science and Technology Commission (Grant Number: cstc2019jcyj-msxmX0364 to Dr. Tang), and CQMU (Chongqing Medical University) Program for Youth Innovation in Future Medicine (to Prof. Chen)."